secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-10-06T23:30:52+00:00
Accession:  0001213900-26-107329
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Turn Therapeutics files Oct 6, 2026 investor presentation; exhibit text shows no financial or pipeline detail
--------------------------------------------------------------------------------

- Turn Therapeutics (Nasdaq: TTRX) furnished an updated corporate/investor presentation dated October 6, 2026 under Item 7.01 (Regulation FD).
- Exhibit 99.1 as attached contains only the title line 'Corporate Presentation October 2026' — no revenue, cash, trial, pipeline, or guidance figures are present.
- Filing signed October 6, 2026 by CEO Bradley Burnam; registrant address is 250 N. Westlake Blvd., Westlake Village, California 91362.
- Because no substantive operating or financial data was disclosed, no directional read on the company's results is possible from this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026107329/0001213900-26-107329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026107329/ea0307911-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-107329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer